Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$17.01 USD
-0.30 (-1.73%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $17.54 +0.53 (3.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PIRS 17.01 -0.30(-1.73%)
Will PIRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PIRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PIRS
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
PIRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
Other News for PIRS
Biotech Alert: Searches spiking for these stocks today
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?